Video

Samsung Biologics Capacity Update October 2025: Large Molecule

Taking a new cancer therapy from discovery to the clinic is a long and costly process. Patient-derived organoids (PDOs) offer a more efficient path by providing models that more closely reflect patient tumor biology and better predict clinical outcomes. Samsung Organoids combines a diverse biobank with advanced assays and high quality scientific service to help partners accelerate discovery while strengthening confidence in translational decisions.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Samsung Biologics